Loading...
Genmab A/S
GNMSF•PNK
HealthcareBiotechnology
$218.13
$6.13(2.89%)
Genmab A/S (GNMSF) Financial Performance & Statements
Review Genmab A/S’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
30.67%
↑ 30.67%
Operating Income Growth
25.97%
↑ 25.97%
Net Income Growth
80.24%
↑ 80.24%
Operating Cash Flow Growth
5.30%
↑ 5.30%
Operating Margin
33.65%
↑ 33.65%
Gross Margin
95.35%
↑ 95.35%
Net Profit Margin
37.10%
↑ 37.10%
ROE
25.61%
↑ 25.61%
ROIC
104.46%
↑ 104.46%
Genmab A/S (GNMSF) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Genmab A/S stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $6.44B | $5.54B | $5.40B | $4.14B |
| Cost of Revenue | $337.00M | $273.00M | $190.00M | $185.00M |
| Gross Profit | $6.10B | $5.27B | $5.21B | $3.96B |
| Gross Profit Ratio | $0.95 | $0.95 | $0.96 | $0.96 |
| R&D Expenses | $2.66B | $2.28B | $2.50B | $2.30B |
| SG&A Expenses | $1.25B | $865.00M | $894.00M | $857.00M |
| Operating Expenses | $3.94B | $3.17B | $3.40B | $3.16B |
| Total Costs & Expenses | $4.28B | $3.44B | $3.59B | $3.34B |
| Interest Income | $224.00M | $162.00M | $292.00M | $295.00M |
| Interest Expense | $54.00M | $18.00M | $19.00M | $7.00M |
| Depreciation & Amortization | $115.00M | $112.00M | $292.00M | $60.00M |
| EBITDA | $2.35B | $1.85B | $2.15B | $1.72B |
| EBITDA Ratio | $0.37 | $0.33 | $0.40 | $0.42 |
| Operating Income | $2.16B | $2.10B | $1.64B | $801.00M |
| Operating Income Ratio | $0.34 | $0.38 | $0.30 | $0.19 |
| Other Income/Expenses (Net) | $1.44B | -$383.00M | $487.00M | $915.00M |
| Income Before Tax | $3.60B | $1.72B | $2.13B | $1.72B |
| Income Before Tax Ratio | $0.56 | $0.31 | $0.39 | $0.41 |
| Income Tax Expense | -$243.00M | $453.00M | $719.00M | $391.00M |
| Net Income | $3.85B | $1.27B | $1.41B | $1.32B |
| Net Income Ratio | $0.60 | $0.23 | $0.26 | $0.32 |
| EPS | $60.51 | $19.94 | $21.85 | $20.29 |
| Diluted EPS | $59.93 | $19.81 | $21.70 | $20.18 |
| Weighted Avg Shares Outstanding | $64.16M | $63.49M | $64.44M | $65.30M |
| Weighted Avg Shares Outstanding (Diluted) | $63.96M | $63.91M | $64.88M | $65.66M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan